A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Key Inclusion Criteria:

• Signed informed consent obtained prior to participation in the study

• Male and female adult participants >= 18 years of age

• CSU duration for >= 6 months prior to screening (defined as the onset of CSUdetermined by the Investigator based on all available supporting documentation).

• Diagnosis of CSU inadequately controlled by second generation H1-AH at the time ofbaseline (Day 1)

• Documentation of hives within three months before baseline (either at screeningand/or at baseline (Day 1); or documented in the participants' medical history).

• Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for theduration of the study and adhere to the protocol

• Participants had no more than 2 missing UPDD entries (either morning or evening) inthe 7 days prior to baseline (Day 1).

Key Exclusion Criteria:

• Participants unable to tolerate 24-hour ambulatory blood pressure measurement usingautomatic ABPM device

• Ongoing or past history of hypertension and/or SBP >= 140 or =< 90 OR DBP >= 90 or =< 60 mmHg at screening

• Participants working night shifts

• Participants taking/requiring medications prohibited by the protocol (includingthose known to interfere with blood pressure assessments in the study)

• Evidence of clinically significant cardiovascular, neurological, psychiatric,pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders,gastrointestinal disease or immunodeficiency that, in the Investigator's opinion,would compromise the safety of the participant, interfere with the interpretation ofthe study results or otherwise preclude participation or protocol adherence of theparticipant.